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In the first paper of this series (1) it was shown that the membrane antigens 
of cultured Burkitt lymphoma (BL) cells (2, 3) depend not only upon the pres- 
ence of Epstein-Barr virus (EBV) (4), but also upon the extent of the persistent 
EBV  infection.  The  membrane antigens  were demonstrated  by indirect  im- 
munofluorescence tests with live cells and  the standard serum obtained from 
Mutua N., a Burkitt tumor patient, who possessed no detectable isoantibodies 
(3).  The  percentage  of  ceils  with  EBV  antigen  was  determined  by  direct 
immunofluorescence tests with acetone-fixed cell smears and fluorescein isothio- 
cyanate (FITC)-conjugated pooled human gamma globulins (5). In the second 
paper of this series (6) it was shown that cultured blastoid cells of EBV-positive 
lines derived from leukocytes of patients in the acute stage of infectious mono- 
nucleosis  (7)  may possess membrane antigens which  are similar to those de- 
tected in  BL  cells;  and  that  in  the  course of infectious mononucleosis  (IM) 
patients develop antibodies which react with membrane antigens of both BL 
and IM cells.  In both studies observations were made which suggested that the 
* These investigations were supported by the Swedish Cancer Society, the Jane  Coffin 
Childs Memorial Fund  (Project No. 180), "Carl-Bertel Nathhorsts  Vetenskapliga Stiftelse" 
research grants CA-04568 and CA-04747 from the National Institutes  of Health, U.S. Public 
Health Service, and  contract  PH-43-66-477 within  the Special Virus Leukemia Program, 
National Cancer Institute,  National Institutes  of Health,  U.S. Public Health Service. 
Recipient of Postdoctoral  Fellowship 2-F2-CA-16,887-02, National  Cancer Institute, 
U.S. Public Health Service. 
§ Career Award 5-K6-AI-22,683, National Institutes  of Health, U.S. Public Health Serv- 
ice. 
697 698  EB  VIRAL AND CELL MEMBRANE IMIMLVNO]~'LUORESCENCE.  III 
antigens  involved in  the  two  types of immunofluorescence tests  are  distinct. 
Cells  showing membrane  immunofluorescence  (MIF)  generally  exceed  those 
containing EBV antigens by a  factor of more than 10. There was no constant 
ratio between MIF-positive and EBV-positive cells, and cells from biopsies or 
recently  initiated  cultures  of  Burkitt  tumors  often revealed  the  presence  of 
membrane antigens, while none, as a  nile, contained detectable EBV antigens. 
Finally, antibodies to membrane antigens were found to develop in the course 
of IM at an apparently slower rate than those to EBV antigens. 
The  indirect  MIF  test  has  been  replaced  recently  by  blocking  of  direct 
membrane immunofluorescence. It was shown  1 that conjugation of the gamma 
globulin fraction of the standard  Mutua  serum with  FITC yielded a  reagent 
suitable for direct staining  of membrane antigens.  The direct staining  of cells 
with this reagent correlated well with results obtained by the indirect technique, 
in  that  both  procedures  stained  similar  percentages  of cells  in positive  lines 
and gave no reactions with cells of negative lines. The direct staining technique 
offers the prospect of a  more refined tool for a  critical comparison of antibody 
specificities in various sera than the indirect method, in that it permits blocking 
tests and thereby restricts the assay to the spectrum of antibodies represented 
in the conjugate. Preliminary blocking data demonstrated that direct I~IF was 
inhibited by unlabeled sera from BL patients,  but not by a number of control 
sera, including three isoantisera from multiply transfused patients. 1 This tech- 
nique has been applied now to numerous additional sera from various types of 
donors with known levels of antibodies to EBV. The results to be reported here 
provide further evidence for a  relationship between MIF and EBV, as well as 
for the fact that the tests involve different antigens. 
Materials and Methods 
Cells.--The establishment  and maintenance  of the cell lines used in these investigations 
from Burkitt tumor biopsies and peripheral leukocytes of IM patients  have been described 
elsewhere (7, 8). 
Sera.--The sera used in this study were obtained  from patients  with different malignant 
and nonmalignant  diseases as  described in the text.  Controls  included  sera  derived  from 
healthy African and non-African donors and from four multiply transfused  patients. 
Anti-EBV  Immunofluorescence Test.--The  procedures  for  staining  acetone-fixed  tissue 
culture cells by direct and indirect immunofluorescence and for the titration of antibodies  to 
EBV have been fully described (5, 9). 
Direct Membrane Immunofluorescence.--The  preparation  of the direct membrane  staining 
reagent,  F-Mutua  (gamma  globulin  fraction  of standard  Mutua  serum  conjugated  with 
FITC), from an antiserum  obtained  from Mrican Burkitt's lymphoma patient  Mutua N. 
(Kenya Cancer Council [K.C.C.] No. 454), which is used as the standard reference serum  to 
demonstrate  the presence of distinctive membrane antigen(s) on BL and IM ceils (1, 6), has 
been described in detail.  1 The procedure for direct membrane staining on living BL and IM 
1 Goldstein, G., G. Klein,  G. Pearson,  and P. Clifford. 1968. Direct  membrane immuno- 
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cells has also been described.  1 In blocking tests, the cells were first incubated with unlabeled 
serum. Mter washing, the cells were then incubated with F-Mutua and processed in the usual 
manner.  1 The results of blocking tests are expressed as blocking indices (BI). The latter are 
calculated by subtracting the per cent positive cells after incubation with unlabeled serum 
followed by the conjugate, from the per cent positives with conjugate alone without unlabeled 
erum, divided by the latter, t 
RESULTS 
Sera from patients with Burkitt's lymphomas (BL), cancer of the postnasal 
space (Ca PNS), and infectious mononucleosis (IM), as well as various control 
sera,  were  tested  for  antibodies  capable  of  inhibiting  the  direct  membrane 
staining of BL cells by F-Mutua. The blocking indices (BI) of these sera were 
plotted against their anti-EBV titers. Three or more blocking tests were per- 
formed with each serum and the average BI calculated. The results of all sera 
tested for both reactivities are shown in Fig. 1. Different symbols are employed 
for sera from various groups of individuals. In general, sera with high anti-EBV 
titers  yielded  high  BI values  (40  of  the  sera  studied  gave anti-EBV  titers 
_>--160 and BI >0.5), while sera that were negative or low with regard to anti- 
EBV activity failed to block F-Mutua to any significant extent (55 of the sera 
studied gave anti-EBV titers =< 80 and BI < 0.5). Several exceptions were noted, 
however, in that seven sera showed low anti-EBV reactions (_-<80) but a high 
BI (>0.5),  and another eight sera revealed high anti-EBV titers (_>-160) and 
a  low  BI  (<0.5).  These  discordant  sera,  providing  evidence  that  different 
antibodies are involved in the two reactions, have been subjected  to further 
intensive study as will be reported separately (10). 
The various categories of sera were analyzed separately as shown in Fig. 2. 
It can be seen that 18 of 20 African Burkitt patients' sera tested (Fig. 2, chart 
A)  had both high anti-EBV and high  blocking activity. The two discordant 
sera with high anti-EBV titers (==_  150),  but low BI values (<0.5)  came from 
a single patient, and were taken either shortly prior to recurrence of the tumor 
after a long-term regression, or later, after intensive chemotherapy. If the total 
number of sera tested are considered, including  those which were tested only 
once or twice in the blocking test, 48 of 61 African Burkitt patients' sera had 
both  high  anti-EBV  and  high  blocking  activity.  Three  of  six  non-African 
Burkitt  patients'  sera  tested  had  anti-EBV  and  blocking  reactivities  either 
both high or both low. 
The BI values of IM sera (Fig. 2, chart B) also seem to correlate well with 
anti-EBV titers. The negative serum was a pre-IM serum and those with low 
BI values were early acute stage sera (11). In general, it appears that anti-EBV 
titers,  as well as BI values attained  in IM, are somewhat lower than in the 
cases of BL. 
Sera from patients with  Ca PNS  (12)  seem to fall into two major groups 
(Fig.  2,  chart C):  (a)  sera with high  anti-EBV  and high  blocking levels  (19 E 
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sera); and (b) sera with low anti-EBV and low BI values (10 sera). Again, there 
seems to be a correlation between anti-EBV titer and BI, but some exceptions 
were noted. Three sera gave low anti-EBV and high blocking values, and seven 
sera gave high anti-EBV titers and low BI values. 
The results obtained with control sera, including  four different isoantisera, 
and sera from patients with nontumor diseases are shown in Fig. 2, chart D. 
It is especially noteworthy that the isoantisera gave low BI values, correlating 
with  their low anti-EBV fiters,  even though they reacted strongly with  the 
membranes  of  BL  and  IM  cells,  as  shown  by indirect  immunofluorescence 
tests (3). This group also contained sera from relatives of Burkitt's lymphoma 
patients. These sera have been of particular importance in providing evidence 
that two antibodies are involved in the different reactions (10). 
Sera from patients with other types of tumors are shown in Fig. 2, chart E. 
Different symbols have been used to distinguish sera from patients with head 
or neck tumors from sera from patients with tumors in other regions. It can be 
seen that sera from the first group tended to react either strongly or weakly in 
both tests, similar to the observations made with sera from Ca PNS patients. 
The second category of sera gave mainly low anti-EBV and low BI values. 
DISCUSSION 
Antibodies reacting with living Burkitt tumor or IM cell membranes (2, 3, 6) 
and with acetone-fixed cell smears (5, 7, 9) have been detected with the use of 
indirect fluorescent techniques.  These investigations have provided evidence 
that EBV is related, in some way, to the expression of membrane antigen(s) 
on BL or  IM  cells.  In  such  indirect systems, however, it is  not feasible  to 
compare the specificities of antibodies in different sera. It is conceivable, there- 
fore,  that  antibodies  detected  in  different  sera  are  reacting  with  different 
antigen(s)  expressed in or on the same cell. The use of direct membrane im- 
munofluorescence, however, eliminates this problem by allowing for blocking 
tests which will only detect antigenic sites common to the blocking and labeled 
sera.  Furthermore,  recent  evidence  (10)  suggests  that  blocking  is  a  "titer- 
related" function which permits  a  quantitative,  as well as qualitative,  com- 
parison between sera. 
The conjugate used for the blocking tests described above was prepared from 
serum of an African Burkitt's lymphoma patient, Mutua N3 His serum has 
previously been shown to be free of detectable isoantibodies (3) and has been 
used as the standard reference serum to demonstrate the presence of distinctive 
membrane antigen(s) on BL and IN[ cells (1, 6). 
Comparison of anti-EBV titers with the blocking indices (BI)  of sera from 
patients with BL, IM, Ca PNS, as well as from various control groups, permits 
a number of conclusions or suggestions. In general, it was found that sera with 
high  anti-EBV titers gave high  BI values and  vice versa,  but  a  number  of 
exceptions were noted. These involved several groups of patients. ~:r~v.~ ~:r  AL.  703 
The  majority  d  the  sera  from patients  with  BL  revealed high  levels  of 
reactivity in both tests. Low BI values but high anti-EBV were noted in several 
sera from one patient, which might be referable to different stages of the disease, 
and  to treatment by chemotherapy. Further study is needed to clarify this 
point. It is conceivable that membrane-reactive antibodies are removed from 
the circulation during recurrence of the tumor, possibly by adsorption onto the 
growing  tumor  or  by  combination  with  antigen  released  from  tumor  cells 
destroyed by chemotherapy. Furthermore, antibody levels may decline as  a 
result of the immunosuppressive action of the therapy, although this has not 
been noted with respect to anti-EBV antibodies. 
TABLE I 
Summary of Results Obtained with 279 Sera in Blocking of Membrane Immunofluorescence 
and Anti-EBV Titrations 
Blocking Index 
High (~ 0.5) 
Low (<0.5) 
High (=>160) 
75  (+27) 
102/279  =  37% 
17  (+14) 
31/279  =  11% 
Anfi-EBV titer 
Low (_~80) 
17  (+5)* 
22/279  =  8% 
97  (+27) 
124/279  =  44% 
* Figures in parentheses represent the number of sera that have been tested only once  in 
blocking tests; all other sera have been tested two or more times. 
Patients with Ca PNS seem to fall into two groups: (a) one with high anti- 
EBV and high BI values; (b) one with low anti-EBV and low BI values. Sera 
from patients with other tumors of the head or neck region also seem to fall into 
these two groups. With regard to Ca PNS, it may be interesting to compare 
the histology of tumors in these two groups, since this class of malignancies is 
undoubtedly not uniform. 
The exceptions in the correspondence of the results of the two assays provide 
further evidence that different antibodies are involved in the respective reac- 
tions.  It is evident that, under some circumstances, one antibody is present, 
unaccompanied by the other. These "discrepancies" will be analyzed further in 
the succeeding report (10). 
Sera tested  for both  antibodies  can  be divided into four different groups 
(Table I): those showing (a) high anti-EBV titers (1:160 or more) and high BI 
values (0.5 or more); (b) low anti-EBV (1:80 or less) and low BI (less than 0.5) ; 
(c) high anti-EBV and low BI; and (d) low anti-EBV and high BI. The majority 
of the two tests agree in that they either gave high or low values in both tests; 
this was the case in approximately 80 % of the sera. This type of distribution 
would not be expected if the expression of each antigen was entirely independent 704  EB VIRAL AND  CELL MEMBRANE  IMM-UNO]~LUORESCENCE. III 
of the other. If they were independent, one would expect a random distribution. 
These results suggest, therefore, that the expression of both types of antigens 
are interrelated. It is tempting to speculate that the virus controls the produc- 
tion of the membrane antigen(s), as appears to be true with oncogenic DNA 
viruses of animals (d. 13). 
Sara from patients with Burkitt's lymphoma (BL), infectious mononucleosis 
(IM), carcinoma of the postnasal space (Ca PNS),  and various controls were 
investigated for antibodies against the Epstein-Barr virus (EBV) by immuno- 
fluorescence on acetone-fixed smears (5) and for antibodies against the distinc- 
tive  antigenic sites  expressed  on  the  surface  of viable  lymphoblastoid cells 
within EBV-carrying culture lines (1). The latter were studied by the blocking 
of direct membrane staining with FITC-conjugated Mutua serum. This serum 
has been derived from a  Burkitt's lymphoma patient in long-term regression 
after chemotherapy and is free from detectable isoantibodies. It has been used 
previously as a standard of reference to demonstrate the presence of the mem- 
brane antigen(s) on all lines derived from BL biopsies and leukocytes from IM 
patients. It was found that 102 of 279 (37 %) of the sara tested had high anti- 
EBV titers  (_->80) and high membrane-blocking (BI >  0.5)  activity, 124 of 
279  (44%)  of the sara were low in both tests, 22  of 279  (8%)  had low EBV 
titers (=<80), in spite of a high blocking index, and 31 of 279 (11%) of the sera 
were low in blocking activity (<0.5),  in spite of a  high EBV titer. The two 
tests thus gave concordant results with 81% and discordant with 19 % of the 
sara. 
The majority of sara from BL patients were high in both tests. IM sara also 
showed a relationship between the two antibody activities but, in general, both 
activities were lower than in BL cases. Ca PNS sara seemed to fall into two 
main  groups:  (a)  high  anti-EBV,  high  blocking  or  (b)  low  anti-EBV,  low 
blocking. Control sara, including four isoantisera, showed predominantly low 
reactivities in both tests. 
BIBLIOGRAPHY 
1.  Klein,  G.,  G.  Pearson,  J.  S. Nadkarni, J. J. Nadkarni, E.  Klein,  P.  Clifford, 
G. Henle, and W. Henle.  1958. Relation between Epstein-Barr  viral and cell 
membrane immunofluorescence of Burkitt tumor cells. I. Dependence  of cell 
membrane  immunofluorescence on presence of EB virus.  J.  Exp.  Med.  128: 
1011. 
2.  Klein,  G.,  P.  Clifford, E.  Klein,  and J.  Stjernsw~ird. 1966. Search  for  tumor 
specific immune reactions  in Burkitt lymphoma patients by the membrane 
immunofluorescence reaction. Proc. Nat.  Acad.  Sci.  U.S.A. 55:1628. 
3.  Klein, G., P. Clifford, E. Klein, R. T. Smith, J. Minowada, F. M. Kourilsky, and 
J.  H.  Burchenal.  1957. Membrane immunofluorescence reactions  of Burkitt KLEIN  ET  AL.  705 
lymphoma cells from biopsy specimens  and  tissue  cultures.  J.  Nat.  Cancer 
Inst. 39:1024. 
4.  Epstein, M. A., Y. M. Barr, and B. G. Achong.  1965. Studies  on Burkitt's lym- 
phomas. Wistar Inst. Syrup. Monogr. 4:69. 
5.  Henle, G., and W. Henle. 1966. Immunofluorescence in cells derived from Bur- 
kitt's lymphoma. J. Bacteriol. 91:1248. 
6.  Klein, G., G. Pearson, G. Henle, W. Henle, V. DieM, and J. C. Niederman. 1968. 
Relation between Epstein-Barr viral and cell membrane immunofluorescence 
in Burkitt  tumor cells. II. Comparison of cells and  sera from patients with 
Burkitt's lymphoma and infectious mononucleosis.  J. Exp. Med.  128:1021. 
7.  DieM,  V.,  G. Henle, W. Henle, and G. Kohn.  1968. Demonstration of a herpes 
group virus  (EBV)  in  cultures  of peripheral leukocytes from patients with 
infectious mononucleosis.  J. Virol. 2:663. 
8.  Nadkarni, J. S., J. J. Nadkarni, P. Clifford,  G. Manolov, E. M. FenyS, and E. 
Klein. 1968. Characteristics of new cell lines derived from Burkitt lymphomas. 
Cancer, In press. 
9.  Henle, G., W. Henle, and V. Diehl. 1968. Relation of Burkitt's tumor-associated 
herpes-type virus  to infectious mononucleosis.  Proc.  Nat.  Acad.  Sci.  U.S.A. 
59:4. 
10.  Pearson, G., G. Klein, G. Henle, W. Henle, and P. Clifford.  1968. Relation be- 
tween Epstein-Barr viral and cell membrane immunofluorescence  in Burkitt 
tumor cells. IV. Differentiation between antibodies responsible  for membrane 
and viral immunofluorescence.  J. Exp. Med. 129:707. 
11.  Niederman, J. C., R. W. McCollum, G. Henle, and W. Henle. 1968. Infectious 
mononucleosis.  Clinical  manifestations in relation to EB  virus antibodies. J. 
Amer. Med. Ass. 203:205. 
12.  Old, L. J., E. A. Boyse, H. F. Oettgren, E. de Harven, G. Geering,  B. William- 
son, and P. Clifford.  1966. Precipitating antibody in human serum to an anti- 
gen present in cultured Burkitt's lymphoma cells. Proc. Nat. Acad. Sci. U.S.A. 
56:1699. 
13.  Klein, G. 1966. Tumor antigens. Annu. Rev. Microbial. 20:223. 